MedTrace Logo

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

NCT05407311 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-11-17

Study results available
· View outcomes & findings →

Summary

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with prostate-specific membrane antigen (PSMA)-negative biochemical recurrence of prostate cancer following definitive therapy.

Conditions

  • Biochemical Recurrence of Malignant Neoplasm of Prostate

Interventions

DRUG

64Cu-SAR-BBN

64Cu-SAR-BBN

Sponsors & Collaborators

  • Clarity Pharmaceuticals Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2024-05-13
Completion
2024-05-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05407311 on ClinicalTrials.gov